SEC Form 4 · accession 0001179110-15-014439
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregg H Alton
Officer — EVP, Corp & Med Affairs
Period of report
Nov 2, 2015
Accepted (ET)
Nov 4, 2015 · 2:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2015 | M | 10,000 | $24.295 | A | 143,422 | D | |
| Common StockF3 | Nov 2, 2015 | S | 6,140 | $109.0986 | D | 137,282 | D | |
| Common StockF4 | Nov 2, 2015 | S | 5,860 | $109.6658 | D | 131,422 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $24.295 | Nov 2, 2015 | M | 10,000 | D | — | Jan 26, 2022 | Common Stock | 10,000 | 118,742 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $108.48 to $109.48. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $109.4825 to $109.8624. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.